A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Annexon, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 401,400 shares of ANNX stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
401,400
Previous 584,200 31.29%
Holding current value
$2.65 Million
Previous $2.86 Million 16.98%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.49 - $7.2 $820,772 - $1.32 Million
-182,800 Reduced 31.29%
401,400 $2.38 Million
Q2 2024

Aug 09, 2024

SELL
$4.33 - $6.79 $376,710 - $590,730
-87,000 Reduced 12.96%
584,200 $2.86 Million
Q1 2024

May 13, 2024

BUY
$4.03 - $7.81 $753,610 - $1.46 Million
187,000 Added 38.62%
671,200 $4.81 Million
Q4 2023

Feb 13, 2024

SELL
$1.63 - $4.63 $125,689 - $357,019
-77,110 Reduced 13.74%
484,200 $2.2 Million
Q3 2023

Nov 14, 2023

BUY
$2.13 - $3.84 $296,304 - $534,182
139,110 Added 32.95%
561,310 $1.33 Million
Q2 2023

Aug 11, 2023

BUY
$2.1 - $6.37 $136,710 - $414,687
65,100 Added 18.23%
422,200 $1.49 Million
Q1 2023

May 12, 2023

BUY
$3.74 - $7.46 $175,780 - $350,620
47,000 Added 15.16%
357,100 $1.38 Million
Q4 2022

Feb 13, 2023

SELL
$4.56 - $6.61 $91,655 - $132,861
-20,100 Reduced 6.09%
310,100 $1.6 Million
Q3 2022

Nov 14, 2022

SELL
$3.75 - $6.63 $111,375 - $196,911
-29,700 Reduced 8.25%
330,200 $2.04 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $4.06 $499,287 - $960,713
-236,629 Reduced 39.67%
359,900 $1.36 Million
Q1 2022

May 13, 2022

BUY
$2.73 - $11.94 $1.35 Million - $5.92 Million
495,629 Added 491.21%
596,529 $1.63 Million
Q4 2021

Feb 11, 2022

BUY
$11.49 - $22.0 $1.16 Million - $2.22 Million
100,900 New
100,900 $1.16 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $315M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.